A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approxima...
Saved in:
| Published in | Vaccine Vol. 16; no. 20; pp. 1901 - 1906 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Elsevier Ltd
01.12.1998
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 |
| DOI | 10.1016/S0264-410X(98)00226-6 |
Cover
| Abstract | In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to
Bordetella pertussis infection were higher (
p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml
−1 had a 67% (
18
27
) chance of infection regardless of the PT value. If the pertactin value was ≥ 7 EU ml
−1 and the PT value ≥ 66 EU ml
−1 all subjects were non-cases. If the pertactin value was ≥ 7 and the PT value was < 66 EU ml
−1 the predicted probability of being a case was 31% (
15
49
). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or
PT
FHA
vaccines. |
|---|---|
| AbstractList | In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis, infection were higher (p<0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of <7 EU ml super(-1) had a 67% (18/27) chance of infection regardless of the PT value. If the pertactin value was greater than or equal to 7 EU ml super(-1) and the PT value greater than or equal to 66 EU ml super(-1) all subjects were non-cases. If the pertactin value was greater than or equal to 7 and the PT value was <66 EU ml super(-1) the predicted probability of being a case was 31% (15/49). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT/FHA vaccines. In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis infection were higher (p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml-1 had a 67% (18/27) chance of infection regardless of the PT value. If the pertactin value was > or = 7 EU ml-1 and the PT value > or = 66 EU ml-1 all subjects were non-cases. If the pertactin value was > or = 7 and the PT value was < 66 EU ml-1 the predicted probability of being a case was 31% (15/49). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT/FHA vaccines. In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis infection were higher ( p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml −1 had a 67% ( 18 27 ) chance of infection regardless of the PT value. If the pertactin value was ≥ 7 EU ml −1 and the PT value ≥ 66 EU ml −1 all subjects were non-cases. If the pertactin value was ≥ 7 and the PT value was < 66 EU ml −1 the predicted probability of being a case was 31% ( 15 49 ). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT FHA vaccines. In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis infection were higher (p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml-1 had a 67% (18/27) chance of infection regardless of the PT value. If the pertactin value was > or = 7 EU ml-1 and the PT value > or = 66 EU ml-1 all subjects were non-cases. If the pertactin value was > or = 7 and the PT value was < 66 EU ml-1 the predicted probability of being a case was 31% (15/49). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT/FHA vaccines.In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable time periods in DT vaccine recipients. In addition, sera were collected from a randomized sample of subjects in each vaccine group at approximately 3-month intervals from which antibody kinetic curves were constructed, which allowed us to estimate specific antibody values to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin and fimbriae-2 at the time of exposure in the household setting. The imputed geometric mean antibody values to PT, pertactin and fimbriae-2 at the time of household exposure to Bordetella pertussis infection were higher (p < 0.07 or lower) in non-cases compared with cases. A multivariate (classification tree) analysis found that only pertactin and PT were significant in protection. Subjects with an imputed pertactin value of < 7 EU ml-1 had a 67% (18/27) chance of infection regardless of the PT value. If the pertactin value was > or = 7 EU ml-1 and the PT value > or = 66 EU ml-1 all subjects were non-cases. If the pertactin value was > or = 7 and the PT value was < 66 EU ml-1 the predicted probability of being a case was 31% (15/49). Logistic regression analysis also found that high versus low pertactin values were associated with illness prevention following household exposure. In the presence of antibody to pertactin, PT and fimbriae-2, the additional presence of antibody to FHA did not contribute to protection. Our data support historical data indicating that agglutinating antibodies are associated with protection and also recent serologic correlates data and clinical efficacy data which indicate that multicomponent vaccines containing pertactin and fimbriae have better efficacy than PT or PT/FHA vaccines. |
| Author | Heininger, Ulrich Stehr, Klemens Cherry, James D Gornbein, Jeffrey |
| Author_xml | – sequence: 1 givenname: James D surname: Cherry fullname: Cherry, James D email: jcherry@pediatrics.emdsch.ucla.edu organization: Department of Pediatrics and the UCLA Centre for Vaccine Research, University of California, Los Angeles (UCLA), School of Medicine, Los Angeles, CA, USA – sequence: 2 givenname: Jeffrey surname: Gornbein fullname: Gornbein, Jeffrey organization: Department of Biomathematics, University of California, Los Angeles (UCLA), School of Medicine, Los Angeles, CA, USA – sequence: 3 givenname: Ulrich surname: Heininger fullname: Heininger, Ulrich organization: Klinik mit Poliklinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Loschgestr. 15, D-91054 Erlangen, Germany – sequence: 4 givenname: Klemens surname: Stehr fullname: Stehr, Klemens organization: Klinik mit Poliklinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Loschgestr. 15, D-91054 Erlangen, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1618069$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9796041$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9r3DAQxUVJSTdpP0JAh1Kag9sZyZYseihp6D8I9NAGehNaeZyo2NZWkgv59vFmlz30sqcZmN97DO-dsZMpTsTYBcI7BFTvf4JQdVUj_H5r2ksAIVSlnrEVtlpWosH2hK0OyAt2lvMfAGgkmlN2arRRUOOK3V7xTC75e97HtKwpDvEueO5jSjS4QpnHnodxnKdQHniJ_FNMHRUaBsc3lMqcc8gLPt_d8zAME-VM-SV73rsh06v9PGe3Xz7_uv5W3fz4-v366qbytYBS9Q2K7U_aid4Y4zU2UhLIxomGUGtBuNZKU2eEBtWadVdLb2oveykcAMlz9mbnu0nx70y52DFkv_1tojhnqwFQGpRHQdQItTKwgBd7cF6P1NlNCqNLD3Yf2HJ_vb-77N3QJzf5kA8YKmxBmQX7sMN8ijkn6q0PxZUQp5JcGCyC3ZZon0q024asae1TiVYt6uY_9cH_iO7jTkdL5v8CJZt9oMlTFxL5YrsYjjg8ApOQswQ |
| CODEN | VACCDE |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2008_04_089 crossref_primary_10_1177_205873920601900109 crossref_primary_10_1097_INF_0b013e3182a09b6a crossref_primary_10_1586_14760584_2014_944901 crossref_primary_10_1093_cid_civ077 crossref_primary_10_1097_01_inf_0000166157_21561_78 crossref_primary_10_1128_IAI_67_8_4064_4071_1999 crossref_primary_10_1136_bmjopen_2012_002473 crossref_primary_10_1586_erv_11_147 crossref_primary_10_2217_17460913_3_3_329 crossref_primary_10_1086_589862 crossref_primary_10_1016_j_vaccine_2005_09_062 crossref_primary_10_1128_IAI_01239_10 crossref_primary_10_1016_S1473_3099_17_30190_1 crossref_primary_10_1007_s00112_017_0256_6 crossref_primary_10_1093_infdis_jis182 crossref_primary_10_1128_CVI_00175_07 crossref_primary_10_1128_IAI_00494_07 crossref_primary_10_1542_peds_2015_3973 crossref_primary_10_1086_425003 crossref_primary_10_1371_journal_ppat_1000647 crossref_primary_10_1016_j_vaccine_2017_11_066 crossref_primary_10_1017_S0950268813000071 crossref_primary_10_1186_s12916_021_02005_5 crossref_primary_10_1093_femspd_ftv051 crossref_primary_10_1097_00006454_199909000_00006 crossref_primary_10_1038_srep40328 crossref_primary_10_1128_CVI_05725_11 crossref_primary_10_1093_jpids_piz005 crossref_primary_10_3923_jms_2004_307_311 crossref_primary_10_1016_S0264_410X_00_00029_3 crossref_primary_10_1016_j_vaccine_2014_08_038 crossref_primary_10_1186_1471_2180_10_236 crossref_primary_10_1016_j_vaccine_2021_04_052 crossref_primary_10_1097_AOG_0000000000002438 crossref_primary_10_1128_IAI_68_12_7175_7179_2000 crossref_primary_10_1016_j_jpeds_2008_03_011 crossref_primary_10_1016_j_yapd_2007_03_009 crossref_primary_10_3390_vaccines7040124 crossref_primary_10_1093_cid_ciac432 crossref_primary_10_1128_IAI_67_6_3133_3134_1999 crossref_primary_10_1080_22221751_2018_1564630 crossref_primary_10_1016_j_vaccine_2016_07_011 crossref_primary_10_1080_21645515_2015_1136759 crossref_primary_10_1016_S0264_410X_03_00407_9 crossref_primary_10_1586_erv_09_88 crossref_primary_10_1038_mi_2014_55 crossref_primary_10_1016_j_puhe_2004_08_018 crossref_primary_10_4049_jimmunol_177_11_7980 crossref_primary_10_1016_S1074_7613_02_00294_7 crossref_primary_10_1586_14760584_2014_935765 crossref_primary_10_1586_14760584_2014_935766 crossref_primary_10_1128_IAI_68_3_1735_1739_2000 crossref_primary_10_1371_journal_pbio_3000697 crossref_primary_10_3201_eid0707_017708 crossref_primary_10_1128_IAI_06310_11 crossref_primary_10_1016_j_vaccine_2009_08_052 crossref_primary_10_1016_j_vaccine_2005_05_039 crossref_primary_10_1111_j_1574_6976_2010_00257_x crossref_primary_10_1097_00006454_200110000_00011 crossref_primary_10_1155_2014_421486 crossref_primary_10_1136_archdischild_2021_322286 crossref_primary_10_1016_j_coi_2019_03_006 crossref_primary_10_1086_313879 crossref_primary_10_1097_00001432_200106000_00014 crossref_primary_10_3390_ijms232012598 crossref_primary_10_1542_peds_2007_0729 crossref_primary_10_1016_j_vaccine_2010_08_017 crossref_primary_10_4167_jbv_2013_43_2_155 crossref_primary_10_1073_pnas_1324149111 crossref_primary_10_1186_s12865_021_00457_1 crossref_primary_10_1093_cid_cit934 crossref_primary_10_1016_j_vaccine_2023_09_060 crossref_primary_10_3390_vaccines9040365 crossref_primary_10_1006_biol_1999_0209 crossref_primary_10_2460_javma_2001_218_367 crossref_primary_10_1371_journal_pone_0198662 crossref_primary_10_1016_j_meegid_2009_10_007 crossref_primary_10_1021_bi901532z crossref_primary_10_1016_j_ijmm_2004_07_007 crossref_primary_10_1586_14760584_6_1_47 crossref_primary_10_1542_peds_104_6_1381 crossref_primary_10_1016_j_vaccine_2014_08_084 crossref_primary_10_1093_infdis_jiaf023 crossref_primary_10_1093_jpids_piw069 crossref_primary_10_1067_mpd_2000_107796 crossref_primary_10_3390_toxins11100557 crossref_primary_10_2165_11209630_000000000_00000 crossref_primary_10_1016_S0264_410X_98_00228_X crossref_primary_10_1080_23744235_2017_1306101 crossref_primary_10_1136_bmjopen_2017_018594 crossref_primary_10_1016_S0264_410X_00_00253_X crossref_primary_10_1038_s41467_024_46560_w crossref_primary_10_1371_journal_pone_0083449 crossref_primary_10_1007_s40471_015_0041_9 crossref_primary_10_1016_j_clinmicnews_2011_07_005 crossref_primary_10_1080_03079457_2015_1069259 crossref_primary_10_1002_eji_201041187 crossref_primary_10_1080_21645515_2018_1480298 crossref_primary_10_1097_01_inf_0000160915_93979_8f crossref_primary_10_1080_21645515_2016_1259780 crossref_primary_10_1016_j_cellimm_2003_12_001 crossref_primary_10_1586_14760584_2014_930667 crossref_primary_10_1086_322564 crossref_primary_10_1016_S0264_410X_00_00252_8 crossref_primary_10_1128_CVI_00294_06 crossref_primary_10_1016_S0264_410X_98_00227_8 crossref_primary_10_1111_j_1600_065X_2010_00970_x crossref_primary_10_1016_j_vaccine_2007_09_031 crossref_primary_10_1080_21645515_2024_2435134 crossref_primary_10_1128_IAI_00188_10 crossref_primary_10_1128_IAI_74_5_2619_2627_2006 crossref_primary_10_1128_CMR_18_2_326_382_2005 crossref_primary_10_1128_IAI_72_12_7346_7351_2004 crossref_primary_10_1016_j_pep_2005_01_014 crossref_primary_10_1016_S0212_6567_04_79377_4 crossref_primary_10_1080_22221751_2022_2053364 crossref_primary_10_1093_cid_civ695 crossref_primary_10_1080_00365540600891299 crossref_primary_10_1093_femspd_ftv057 crossref_primary_10_1080_14760584_2022_2149499 crossref_primary_10_1186_1471_2180_9_274 crossref_primary_10_1586_erv_09_46 crossref_primary_10_1016_j_clinmicnews_2015_04_001 crossref_primary_10_1016_j_vaccine_2004_08_002 crossref_primary_10_1186_1471_2288_13_29 crossref_primary_10_1016_S0264_410X_99_00164_4 crossref_primary_10_1016_S0264_410X_01_00063_9 crossref_primary_10_1128_CVI_00469_09 crossref_primary_10_1016_j_vaccine_2014_02_005 crossref_primary_10_15585_mmwr_rr6702a1 crossref_primary_10_1016_j_vaccine_2005_06_021 crossref_primary_10_1016_j_vaccine_2007_05_039 crossref_primary_10_1016_j_vaccine_2015_11_049 crossref_primary_10_1093_cid_ciw551 crossref_primary_10_1097_GRF_0b013e318181dde1 crossref_primary_10_1016_j_vaccine_2021_01_041 crossref_primary_10_1099_00221287_147_11_2885 crossref_primary_10_1016_j_vaccine_2006_10_048 crossref_primary_10_1093_cid_cit048 crossref_primary_10_1371_journal_ppat_1003418 crossref_primary_10_1016_S1473_3099_18_30646_7 crossref_primary_10_1016_j_tvjl_2016_04_004 crossref_primary_10_1016_j_vaccine_2013_12_037 crossref_primary_10_1097_00006454_200008000_00018 crossref_primary_10_1080_14760584_2022_2130770 crossref_primary_10_1586_14760584_2_1_113 crossref_primary_10_3201_eid0706_010606 crossref_primary_10_1093_cid_ciu823 crossref_primary_10_1007_s40121_021_00530_7 crossref_primary_10_1016_j_ebiom_2021_103247 crossref_primary_10_1086_322639 crossref_primary_10_1186_s12865_015_0090_3 crossref_primary_10_1016_S1473_3099_07_70113_5 crossref_primary_10_1001_jamanetworkopen_2024_24608 crossref_primary_10_1128_CVI_00665_13 crossref_primary_10_1016_S0264_410X_01_00269_9 crossref_primary_10_1099_mic_0_079251_0 crossref_primary_10_1136_bmjopen_2020_042711 crossref_primary_10_1016_j_vaccine_2012_02_013 crossref_primary_10_1097_INF_0b013e3182717edf crossref_primary_10_1111_j_1600_0463_2009_02521_x crossref_primary_10_1016_S0264_410X_00_00545_4 crossref_primary_10_1056_NEJMe058181 crossref_primary_10_1016_j_vaccine_2013_11_104 crossref_primary_10_1038_mi_2012_54 crossref_primary_10_1128_MMBR_68_4_692_744_2004 crossref_primary_10_1016_S0264_410X_99_00534_4 crossref_primary_10_1016_j_vaccine_2010_04_094 crossref_primary_10_1097_00006454_200101000_00013 crossref_primary_10_1517_14728214_11_2_195 crossref_primary_10_1093_cid_ciz840 crossref_primary_10_1128_CVI_00436_09 crossref_primary_10_1128_CVI_00355_12 crossref_primary_10_1371_journal_pone_0013915 crossref_primary_10_1111_j_1574_695X_2005_00001_x crossref_primary_10_2174_0929866527666200924144908 crossref_primary_10_1016_j_vaccine_2013_05_073 crossref_primary_10_1016_S0264_410X_99_00341_2 crossref_primary_10_1016_S0264_410X_99_00037_7 crossref_primary_10_1016_j_jbi_2017_08_005 crossref_primary_10_1016_j_vaccine_2005_06_009 crossref_primary_10_1128_IAI_72_7_3716_3723_2004 crossref_primary_10_3390_toxins13080508 crossref_primary_10_1080_21505594_2017_1321192 crossref_primary_10_1111_j_1420_9101_2006_01154_x crossref_primary_10_1097_00006454_200206000_00011 crossref_primary_10_1016_j_humimm_2014_02_013 crossref_primary_10_1111_j_1574_6968_2007_00833_x crossref_primary_10_1371_journal_pone_0003665 crossref_primary_10_1016_j_vaccine_2016_06_051 crossref_primary_10_1111_j_1365_3083_2010_02410_x crossref_primary_10_3389_fimmu_2019_01344 crossref_primary_10_1016_j_vaccine_2011_12_048 crossref_primary_10_1128_CVI_05460_11 crossref_primary_10_1016_S1286_4579_01_01421_6 crossref_primary_10_1128_IAI_69_9_5520_5528_2001 crossref_primary_10_1542_peds_2004_2759 crossref_primary_10_1097_00019048_200206000_00009 crossref_primary_10_1016_j_vaccine_2005_11_012 crossref_primary_10_1016_j_vaccine_2011_02_062 crossref_primary_10_1371_journal_pone_0088919 crossref_primary_10_1097_00006454_200104000_00011 crossref_primary_10_1017_S0950268807000192 crossref_primary_10_1177_000992280304200201 crossref_primary_10_1016_S0264_410X_99_00568_X crossref_primary_10_1038_jp_2009_138 crossref_primary_10_1128_CVI_00131_10 crossref_primary_10_3390_vaccines12010108 crossref_primary_10_1128_IAI_72_1_615_620_2004 crossref_primary_10_1371_journal_pone_0083583 crossref_primary_10_1586_14760584_2014_946016 crossref_primary_10_1093_cid_civ700 crossref_primary_10_1128_CDLI_10_4_637_642_2003 crossref_primary_10_1128_IAI_69_8_4846_4850_2001 crossref_primary_10_1586_14760584_2014_946015 crossref_primary_10_1128_CVI_00074_07 crossref_primary_10_1086_313913 crossref_primary_10_1128_IAI_68_7_3873_3877_2000 crossref_primary_10_1016_j_vaccine_2010_02_045 crossref_primary_10_1016_j_vaccine_2016_04_066 crossref_primary_10_1371_journal_pone_0237394 crossref_primary_10_1002_14651858_CD001478_pub6 crossref_primary_10_1128_CVI_00280_14 crossref_primary_10_1371_journal_pone_0284898 crossref_primary_10_1542_peds_107_2_e25 crossref_primary_10_1016_S1473_3099_20_30274_7 crossref_primary_10_1097_01_revmedmi_0000175933_85861_4e crossref_primary_10_1101_cshperspect_a029629 crossref_primary_10_1128_IAI_68_12_7152_7155_2000 crossref_primary_10_1016_j_vaccine_2018_03_029 crossref_primary_10_1016_j_vaccine_2008_11_072 crossref_primary_10_1016_j_vaccine_2010_06_118 crossref_primary_10_1111_j_1365_2249_2006_03097_x crossref_primary_10_1111_cei_13275 crossref_primary_10_1007_BF02932018 crossref_primary_10_1016_j_vaccine_2009_07_092 crossref_primary_10_1172_JCI135020 crossref_primary_10_1016_j_jmb_2023_168344 crossref_primary_10_1016_j_procbio_2017_07_001 crossref_primary_10_1016_S0264_410X_03_00062_8 crossref_primary_10_1371_journal_pone_0085227 crossref_primary_10_1371_journal_pntd_0010657 crossref_primary_10_1007_s00112_017_0363_4 crossref_primary_10_2217_fmb_14_77 crossref_primary_10_1128_JCM_43_6_2856_2865_2005 crossref_primary_10_1007_s10096_014_2110_2 crossref_primary_10_1080_14760584_2023_2188942 crossref_primary_10_1128_microbiolspec_EI10_0008_2015 crossref_primary_10_1016_j_vaccine_2005_01_078 crossref_primary_10_1128_CVI_00372_08 crossref_primary_10_1542_peds_2011_2594 crossref_primary_10_1016_j_micpath_2008_01_002 crossref_primary_10_1002_sim_2282 crossref_primary_10_1016_j_vaccine_2012_06_005 crossref_primary_10_1542_peds_2021_052061 crossref_primary_10_1128_CVI_00641_13 crossref_primary_10_3390_diseases7020035 crossref_primary_10_1007_s10875_015_0131_y crossref_primary_10_1097_INF_0000000000001366 crossref_primary_10_1016_j_crmicr_2024_100291 crossref_primary_10_1038_s41385_021_00407_5 crossref_primary_10_1055_a_2471_6906 crossref_primary_10_1084_jem_191_11_1841 crossref_primary_10_1016_j_vaccine_2011_11_035 crossref_primary_10_1016_S0140_6736_06_68848_X crossref_primary_10_1038_s41598_018_30558_8 crossref_primary_10_1093_cid_ciw027 crossref_primary_10_1016_j_vaccine_2020_09_003 crossref_primary_10_1016_j_vaccine_2005_01_087 crossref_primary_10_1080_00365540701642138 crossref_primary_10_1586_14760584_2014_936391 crossref_primary_10_1016_S0264_410X_03_00107_5 crossref_primary_10_1093_femsle_fny142 crossref_primary_10_1128_IAI_00769_08 crossref_primary_10_1016_j_ajog_2010_11_024 crossref_primary_10_1016_j_vaccine_2022_12_071 crossref_primary_10_1016_S0399_077X_01_80092_5 crossref_primary_10_1097_INF_0b013e318262528c crossref_primary_10_1016_S0264_410X_01_00029_9 crossref_primary_10_1093_cid_cit684 crossref_primary_10_1097_MOP_0000000000000139 crossref_primary_10_1016_j_vaccine_2014_09_019 crossref_primary_10_1128_IAI_70_7_3521_3528_2002 crossref_primary_10_3389_fimmu_2020_605273 crossref_primary_10_1093_infdis_jit488 crossref_primary_10_1016_j_micinf_2018_02_002 crossref_primary_10_1080_21645515_2016_1234555 crossref_primary_10_3928_0090_4481_20040801_10 crossref_primary_10_1016_j_vaccine_2008_04_016 crossref_primary_10_1016_S2213_2600_15_00294_5 crossref_primary_10_1007_s00430_021_00718_1 |
| Cites_doi | 10.1056/NEJM199602083340601 10.1093/clinids/21.5.1211 10.1016/S0264-410X(98)00227-8 10.1016/S0022-3476(97)70234-8 10.1542/peds.81.6.933 10.1542/peds.102.3.546 10.1016/0264-410X(90)90246-I 10.1097/00006454-199503000-00008 10.1001/jama.275.1.37 10.1016/0264-410X(92)90113-X 10.1097/00006454-199711000-00007 10.1016/S0022-3476(47)80280-X 10.1056/NEJM199510193331604 10.1097/00006454-199705000-00012 10.1093/clinids/1.3.401 10.1097/00006454-199306000-00009 10.1111/j.1749-6632.1995.tb44470.x 10.1016/S0264-410X(97)00100-X 10.1097/00006454-199704001-00004 10.1093/infdis/174.Supplement_3.S259 10.1542/peds.102.4.909 10.1056/NEJM199602083340602 10.1016/0264-410X(94)90014-0 10.1016/S0022-3476(43)80220-1 10.1542/peds.101.1.1 10.1016/S0140-6736(97)06508-2 |
| ContentType | Journal Article |
| Copyright | 1998 1999 INIST-CNRS |
| Copyright_xml | – notice: 1998 – notice: 1999 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T5 C1K H94 7X8 |
| DOI | 10.1016/S0264-410X(98)00226-6 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Immunology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 1906 |
| ExternalDocumentID | 9796041 1618069 10_1016_S0264_410X_98_00226_6 S0264410X98002266 |
| Genre | Clinical Trial Randomized Controlled Trial Journal Article |
| GeographicLocations | Europe Germany |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3V. 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABLVK ABMAC ABMZM ABRWV ABUWG ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD AEBSH AEFWE AEKER AENEX AESVU AEVXI AEXOQ AFCTW AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HEJ HLV HMCUK HMG HMK HMO HVGLF HX~ HZ~ IHE J1W K9- KOM L7B LCYCR LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 QYZTP R2- RIG ROL RPZ SAB SAE SCC SDF SDG SDP SES SEW SIN SNL SPCBC SSH SSI SSZ SVS T5K UKHRP UV1 WH7 WOW WUQ XPP Z5R ZGI ZXP ~G- AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACMHX ACRPL ACVFH ADCNI ADNMO ADSLC ADVLN AEIPS AEUPX AEUYN AFJKZ AFPUW AGCQF AGQPQ AGRNS AGWPP AIGII AIIUN AKBMS AKRWK AKYEP ALIPV ANKPU APXCP CITATION PHGZM PHGZT EFKBS IQODW PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QL 7T5 ACLOT C1K H94 ~HD 7X8 |
| ID | FETCH-LOGICAL-c420t-f51200057a2f999c71533e035a25e1772e1b767ed9270689bd43c94c3f32a00e3 |
| IEDL.DBID | .~1 |
| ISSN | 0264-410X |
| IngestDate | Sat Sep 27 19:38:14 EDT 2025 Sun Sep 28 10:38:34 EDT 2025 Wed Feb 19 02:33:05 EST 2025 Mon Jul 21 09:15:07 EDT 2025 Tue Jul 01 03:44:01 EDT 2025 Thu Apr 24 23:00:39 EDT 2025 Fri Feb 23 02:31:27 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Keywords | pertussis vaccine immunity to pertussis B. pertussis immunity serologic correlates of immunity Human Immunoprotection Immune response Antibody Hemagglutinin Booster vaccination Glycoprotein Infant Pilus Islet activating protein Serology Bordetella pertussis Polyvalent vaccine Whooping cough Infection Toxin Immunogenicity Bacteriosis Bacteria Humoral immunity |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c420t-f51200057a2f999c71533e035a25e1772e1b767ed9270689bd43c94c3f32a00e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 9796041 |
| PQID | 17104690 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_70013913 proquest_miscellaneous_17104690 pubmed_primary_9796041 pascalfrancis_primary_1618069 crossref_citationtrail_10_1016_S0264_410X_98_00226_6 crossref_primary_10_1016_S0264_410X_98_00226_6 elsevier_sciencedirect_doi_10_1016_S0264_410X_98_00226_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1998-12-01 |
| PublicationDateYYYYMMDD | 1998-12-01 |
| PublicationDate_xml | – month: 12 year: 1998 text: 1998-12-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: Netherlands |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 1998 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Hewlett, Cherry (BIB28) 1997 Heininger, Cherry, Christenson (BIB24) 1994; 12 Trollfors, Taranger, Lagergård (BIB14) 1995; 333 in press. Schläpfer, Cherry, Heininger (BIB22) 1995; 14 Cherry, J.D., Heininger, U., Stehr, K. and Christenson, P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Stehr, Cherry, Heininger (BIB6) 1998; 101 Cherry, Heninger (BIB25) 1998 Sako (BIB5) 1947; 30 Cherry (BIB26) 1992; 10 Olin, Rasmussen, Gustafsson, Hallander, Heijbel (BIB18) 1997; 350 Manclark, Meade, Burstyn (BIB23) 1986 (BIB8) 1988; 1 Miller, Silverberg, Saito, Humber (BIB4) 1943; 22 Simondon, Preziosi, Yam (BIB15) 1997; 15 Storsaeter, Blackwelder, Hallander (BIB9) 1992; 146 Schmitt, Wirsing von König, Neiss (BIB11) 1996; 275 Cherry (BIB30) 1997; 16 Cherry (BIB1) 1996; 174 Olin (BIB32) 1997; 16 Storsaeter, Hallander, Farrington, Olin, Möllby, Miller (BIB10) 1990; 8 Medical Research Council (BIB3) 1956; 2 Heininger, Cherry, Eckhardt, Lorenz, Christenson, Stehr (BIB21) 1993; 12 Gustafsson, Hallander, Olin, Reizenstein, Storsaeter (BIB13) 1996; 334 Storsaeter, Hallander, Gustafsson, Olin (BIB20) 1998; 16 Heininger, Cherry, Stehr (BIB7) 1998; 102 Trolfors, Taranger, Lagergård (BIB17) 1997; 130 Cherry, Brunell, Golden, Darzon (BIB2) 1988; 81 Greco, Salmaso, Biol (BIB12) 1996; 334 Liese, Meschievitz, Harzer (BIB16) 1997; 16 Deen, Mink, Cherry (BIB19) 1995; 21 Pitman (BIB27) 1979; 1 Cherry, Heininger, Christenson (BIB29) 1995; 754 Storsaeter (10.1016/S0264-410X(98)00226-6_BIB20) 1998; 16 Hewlett (10.1016/S0264-410X(98)00226-6_BIB28) 1997 Cherry (10.1016/S0264-410X(98)00226-6_BIB30) 1997; 16 Medical Research Council (10.1016/S0264-410X(98)00226-6_BIB3) 1956; 2 Deen (10.1016/S0264-410X(98)00226-6_BIB19) 1995; 21 (10.1016/S0264-410X(98)00226-6_BIB8) 1988; 1 Storsaeter (10.1016/S0264-410X(98)00226-6_BIB10) 1990; 8 Olin (10.1016/S0264-410X(98)00226-6_BIB32) 1997; 16 Greco (10.1016/S0264-410X(98)00226-6_BIB12) 1996; 334 Trollfors (10.1016/S0264-410X(98)00226-6_BIB14) 1995; 333 Liese (10.1016/S0264-410X(98)00226-6_BIB16) 1997; 16 Olin (10.1016/S0264-410X(98)00226-6_BIB18) 1997; 350 Schmitt (10.1016/S0264-410X(98)00226-6_BIB11) 1996; 275 Simondon (10.1016/S0264-410X(98)00226-6_BIB15) 1997; 15 Heininger (10.1016/S0264-410X(98)00226-6_BIB21) 1993; 12 Heininger (10.1016/S0264-410X(98)00226-6_BIB24) 1994; 12 Sako (10.1016/S0264-410X(98)00226-6_BIB5) 1947; 30 Cherry (10.1016/S0264-410X(98)00226-6_BIB2) 1988; 81 Stehr (10.1016/S0264-410X(98)00226-6_BIB6) 1998; 101 Pitman (10.1016/S0264-410X(98)00226-6_BIB27) 1979; 1 Cherry (10.1016/S0264-410X(98)00226-6_BIB29) 1995; 754 Cherry (10.1016/S0264-410X(98)00226-6_BIB25) 1998 Cherry (10.1016/S0264-410X(98)00226-6_BIB1) 1996; 174 Schläpfer (10.1016/S0264-410X(98)00226-6_BIB22) 1995; 14 Storsaeter (10.1016/S0264-410X(98)00226-6_BIB9) 1992; 146 Heininger (10.1016/S0264-410X(98)00226-6_BIB7) 1998; 102 10.1016/S0264-410X(98)00226-6_BIB31 Cherry (10.1016/S0264-410X(98)00226-6_BIB26) 1992; 10 Manclark (10.1016/S0264-410X(98)00226-6_BIB23) 1986 Gustafsson (10.1016/S0264-410X(98)00226-6_BIB13) 1996; 334 Miller (10.1016/S0264-410X(98)00226-6_BIB4) 1943; 22 Trolfors (10.1016/S0264-410X(98)00226-6_BIB17) 1997; 130 9796040 - Vaccine. 1998 Dec;16(20):1899-900 |
| References_xml | – volume: 2 start-page: 454 year: 1956 end-page: 462 ident: BIB3 article-title: Vaccination against whooping cough: relation between protection in children and results of laboratory tests publication-title: Br. Med. J. – volume: 21 start-page: 1211 year: 1995 end-page: 1219 ident: BIB19 article-title: Household contact study of publication-title: Clin. Inf. Dis. – volume: 350 start-page: 1569 year: 1997 end-page: 1578 ident: BIB18 article-title: For the Ad Hoc Group for the Study of Pertussis Vaccines publication-title: Lancet – volume: 1 start-page: 955 year: 1988 end-page: 960 ident: BIB8 article-title: Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events publication-title: Lancet – volume: 146 start-page: 167 year: 1992 end-page: 172 ident: BIB9 article-title: Pertussis antibodies, protection, and vaccine efficacy after household exposure publication-title: AJDC – volume: 16 start-page: 1038 year: 1997 end-page: 1044 ident: BIB16 article-title: Efficacy of a two-component acellular pertussis vaccine in infants publication-title: Pediatr Infect Dis J. – volume: 16 start-page: S90 year: 1997 end-page: S96 ident: BIB30 article-title: Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials publication-title: Pediatr. Infect. Dis. J. – volume: 333 start-page: 1045 year: 1995 end-page: 1050 ident: BIB14 article-title: A placebocontrolled trial of a pertussis-toxoid vaccine publication-title: N. Engl. J. Med. – start-page: 1423 year: 1998 end-page: 1440 ident: BIB25 article-title: Pertussis and other bordetella infections publication-title: Textbook of Pediatric Infectious Diseases – volume: 334 start-page: 349 year: 1996 end-page: 355 ident: BIB13 article-title: A controlled trial of two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine publication-title: N. Engl. J. Med. – volume: 15 start-page: 1606 year: 1997 end-page: 1612 ident: BIB15 article-title: A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal publication-title: Vaccine – volume: 81 start-page: 939 year: 1988 end-page: 984 ident: BIB2 article-title: Report of the task force on pertussis and pertussis immunization—1988 publication-title: Pediatrics – volume: 275 start-page: 37 year: 1996 end-page: 41 ident: BIB11 article-title: Efficacy of acellular pertussis vaccine in early childhood after household exposure publication-title: JAMA – volume: 334 start-page: 341 year: 1996 end-page: 348 ident: BIB12 article-title: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis publication-title: N. Engl. J. Med. – volume: 754 start-page: 359 year: 1995 end-page: 363 ident: BIB29 article-title: Surrogate serologic tests for the prediction of pertussis vaccine efficacy publication-title: New York Academy of Sciences – volume: 12 start-page: 81 year: 1994 end-page: 86 ident: BIB24 article-title: Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany publication-title: Vaccine – volume: 102 start-page: 546 year: 1998 end-page: 553 ident: BIB7 article-title: Comparative effecacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and the Lederle whole-cell component DTP vaccine in German children following household exposure publication-title: Pediatrics – volume: 8 start-page: 457 year: 1990 end-page: 461 ident: BIB10 article-title: Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial publication-title: Vaccine – start-page: 388 year: 1986 end-page: 394 ident: BIB23 article-title: Serologic response to publication-title: Manual of Clinical Laboratory Immunology – volume: 16 start-page: 1907 year: 1998 end-page: 1916 ident: BIB20 article-title: Levels of antipertussis antibodies over time related to protection after household exposure to publication-title: Vaccine – start-page: 387 year: 1997 end-page: 416 ident: BIB28 article-title: New and improved vaccines against pertussis publication-title: New Generation Vaccines – volume: 14 start-page: 209 year: 1995 end-page: 214 ident: BIB22 article-title: Polymerase chain reaction identification of publication-title: J. Ped. Inf. Dis. – volume: 10 start-page: 1033 year: 1992 end-page: 1037 ident: BIB26 article-title: Pertussis: the trials and tribulations of old and new pertussis vaccines publication-title: Vaccine – volume: 101 start-page: 1 year: 1998 end-page: 11 ident: BIB6 article-title: A comparative efficacy trial in Erlangen, Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine publication-title: Pediatrics – volume: 12 start-page: 504 year: 1993 end-page: 509 ident: BIB21 article-title: Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany publication-title: Pediatr. Infect. Dis. J. – reference: Cherry, J.D., Heininger, U., Stehr, K. and Christenson, P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. – volume: 174 start-page: S259 year: 1996 end-page: S263 ident: BIB1 article-title: Historical review of pertussis and the classical vaccine publication-title: J. Infect Dis. – volume: 22 start-page: 644 year: 1943 end-page: 651 ident: BIB4 article-title: An agglutinative reaction for Hemophilus pertussis: II. Its relation to clinical immunity publication-title: J. Pediatr. – reference: in press. – volume: 1 start-page: 401 year: 1979 end-page: 402 ident: BIB27 article-title: Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis publication-title: Rev. Infect. Dis. – volume: 30 start-page: 29 year: 1947 ident: BIB5 article-title: Studies on pertussis immunization publication-title: J. Pediatr. – volume: 130 start-page: 532 year: 1997 end-page: 536 ident: BIB17 article-title: Efficacy of a monocomponent pertusses toxoid vaccince after household exposure to pertussis publication-title: J. Pediatr. – volume: 16 start-page: 517 year: 1997 end-page: 519 ident: BIB32 article-title: Commentary: the best acellular pertussis vaccines are multicomponent publication-title: Pediatr. Infect. Dis. J. – volume: 334 start-page: 341 year: 1996 ident: 10.1016/S0264-410X(98)00226-6_BIB12 article-title: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199602083340601 – volume: 21 start-page: 1211 year: 1995 ident: 10.1016/S0264-410X(98)00226-6_BIB19 article-title: Household contact study of Bordetella pertussis infections publication-title: Clin. Inf. Dis. doi: 10.1093/clinids/21.5.1211 – volume: 16 start-page: 1907 year: 1998 ident: 10.1016/S0264-410X(98)00226-6_BIB20 article-title: Levels of antipertussis antibodies over time related to protection after household exposure to Bordetella pertussis publication-title: Vaccine doi: 10.1016/S0264-410X(98)00227-8 – volume: 130 start-page: 532 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB17 article-title: Efficacy of a monocomponent pertusses toxoid vaccince after household exposure to pertussis publication-title: J. Pediatr. doi: 10.1016/S0022-3476(97)70234-8 – volume: 81 start-page: 939 year: 1988 ident: 10.1016/S0264-410X(98)00226-6_BIB2 article-title: Report of the task force on pertussis and pertussis immunization—1988 publication-title: Pediatrics doi: 10.1542/peds.81.6.933 – volume: 102 start-page: 546 year: 1998 ident: 10.1016/S0264-410X(98)00226-6_BIB7 article-title: Comparative effecacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and the Lederle whole-cell component DTP vaccine in German children following household exposure publication-title: Pediatrics doi: 10.1542/peds.102.3.546 – volume: 8 start-page: 457 year: 1990 ident: 10.1016/S0264-410X(98)00226-6_BIB10 article-title: Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial publication-title: Vaccine doi: 10.1016/0264-410X(90)90246-I – volume: 146 start-page: 167 year: 1992 ident: 10.1016/S0264-410X(98)00226-6_BIB9 article-title: Pertussis antibodies, protection, and vaccine efficacy after household exposure publication-title: AJDC – volume: 14 start-page: 209 year: 1995 ident: 10.1016/S0264-410X(98)00226-6_BIB22 article-title: Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany publication-title: J. Ped. Inf. Dis. doi: 10.1097/00006454-199503000-00008 – volume: 275 start-page: 37 year: 1996 ident: 10.1016/S0264-410X(98)00226-6_BIB11 article-title: Efficacy of acellular pertussis vaccine in early childhood after household exposure publication-title: JAMA doi: 10.1001/jama.275.1.37 – start-page: 1423 year: 1998 ident: 10.1016/S0264-410X(98)00226-6_BIB25 article-title: Pertussis and other bordetella infections – volume: 10 start-page: 1033 year: 1992 ident: 10.1016/S0264-410X(98)00226-6_BIB26 article-title: Pertussis: the trials and tribulations of old and new pertussis vaccines publication-title: Vaccine doi: 10.1016/0264-410X(92)90113-X – volume: 16 start-page: 1038 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB16 article-title: Efficacy of a two-component acellular pertussis vaccine in infants publication-title: Pediatr Infect Dis J. doi: 10.1097/00006454-199711000-00007 – volume: 30 start-page: 29 year: 1947 ident: 10.1016/S0264-410X(98)00226-6_BIB5 article-title: Studies on pertussis immunization publication-title: J. Pediatr. doi: 10.1016/S0022-3476(47)80280-X – volume: 1 start-page: 955 year: 1988 ident: 10.1016/S0264-410X(98)00226-6_BIB8 article-title: Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events publication-title: Lancet – volume: 333 start-page: 1045 year: 1995 ident: 10.1016/S0264-410X(98)00226-6_BIB14 article-title: A placebocontrolled trial of a pertussis-toxoid vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199510193331604 – volume: 16 start-page: 517 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB32 article-title: Commentary: the best acellular pertussis vaccines are multicomponent publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-199705000-00012 – volume: 1 start-page: 401 year: 1979 ident: 10.1016/S0264-410X(98)00226-6_BIB27 article-title: Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis publication-title: Rev. Infect. Dis. doi: 10.1093/clinids/1.3.401 – volume: 12 start-page: 504 year: 1993 ident: 10.1016/S0264-410X(98)00226-6_BIB21 article-title: Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-199306000-00009 – volume: 754 start-page: 359 year: 1995 ident: 10.1016/S0264-410X(98)00226-6_BIB29 article-title: Surrogate serologic tests for the prediction of pertussis vaccine efficacy publication-title: New York Academy of Sciences doi: 10.1111/j.1749-6632.1995.tb44470.x – volume: 15 start-page: 1606 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB15 article-title: A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal publication-title: Vaccine doi: 10.1016/S0264-410X(97)00100-X – volume: 16 start-page: S90 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB30 article-title: Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-199704001-00004 – volume: 174 start-page: S259 issue: Suppl3 year: 1996 ident: 10.1016/S0264-410X(98)00226-6_BIB1 article-title: Historical review of pertussis and the classical vaccine publication-title: J. Infect Dis. doi: 10.1093/infdis/174.Supplement_3.S259 – start-page: 388 year: 1986 ident: 10.1016/S0264-410X(98)00226-6_BIB23 article-title: Serologic response to Bordetella pertussis – ident: 10.1016/S0264-410X(98)00226-6_BIB31 doi: 10.1542/peds.102.4.909 – volume: 2 start-page: 454 year: 1956 ident: 10.1016/S0264-410X(98)00226-6_BIB3 article-title: Vaccination against whooping cough: relation between protection in children and results of laboratory tests publication-title: Br. Med. J. – volume: 334 start-page: 349 year: 1996 ident: 10.1016/S0264-410X(98)00226-6_BIB13 article-title: A controlled trial of two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199602083340602 – volume: 12 start-page: 81 year: 1994 ident: 10.1016/S0264-410X(98)00226-6_BIB24 article-title: Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany publication-title: Vaccine doi: 10.1016/0264-410X(94)90014-0 – volume: 22 start-page: 644 year: 1943 ident: 10.1016/S0264-410X(98)00226-6_BIB4 article-title: An agglutinative reaction for Hemophilus pertussis: II. Its relation to clinical immunity publication-title: J. Pediatr. doi: 10.1016/S0022-3476(43)80220-1 – volume: 101 start-page: 1 year: 1998 ident: 10.1016/S0264-410X(98)00226-6_BIB6 article-title: A comparative efficacy trial in Erlangen, Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine publication-title: Pediatrics doi: 10.1542/peds.101.1.1 – volume: 350 start-page: 1569 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB18 article-title: For the Ad Hoc Group for the Study of Pertussis Vaccines publication-title: Lancet doi: 10.1016/S0140-6736(97)06508-2 – start-page: 387 year: 1997 ident: 10.1016/S0264-410X(98)00226-6_BIB28 article-title: New and improved vaccines against pertussis – reference: 9796040 - Vaccine. 1998 Dec;16(20):1899-900 |
| SSID | ssj0005319 |
| Score | 2.1230426 |
| Snippet | In a pertussis vaccine efficacy trial in Germany we collected sera from vaccinees (DTaP or DTP) after the third and fourth doses of vaccine or at comparable... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1901 |
| SubjectTerms | Adhesins, Bacterial - immunology Antibodies, Bacterial - blood Antigens, Bacterial - immunology B. pertussis immunity Bacterial Outer Membrane Proteins - immunology Bacterial Proteins - immunology Bacteriology Biological and medical sciences Biomarkers - blood Bordetella pertussis Cohort Studies Diphtheria-Tetanus-acellular Pertussis Vaccines Diphtheria-Tetanus-Pertussis Vaccine - immunology Double-Blind Method Epidemiology. Vaccinations Female Fimbriae Proteins Fimbriae, Bacterial - immunology Fundamental and applied biological sciences. Psychology General aspects Hemagglutinins - immunology Humans immunity to pertussis Immunoglobulin G - analysis Infant Infectious diseases Male Medical sciences Microbiology Multivariate Analysis Pertussis Toxin pertussis vaccine Pertussis Vaccine - immunology Prospective Studies serologic correlates of immunity Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virulence Factors, Bordetella - immunology Whooping Cough - immunology Whooping Cough - prevention & control |
| Title | A search for serologic correlates of immunity to Bordetella pertussis cough illnesses |
| URI | https://dx.doi.org/10.1016/S0264-410X(98)00226-6 https://www.ncbi.nlm.nih.gov/pubmed/9796041 https://www.proquest.com/docview/17104690 https://www.proquest.com/docview/70013913 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1873-2518 dateEnd: 20091019 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1873-2518 dateEnd: 20091019 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AKRWK dateStart: 19831201 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED5Ky8ZglC1bWda108MoG9SNbcmS9ZiWlWyjpbBm5E34h9QFQhJi5yEv_dunk-x6fQiFvhmhk43udPdh3X0H8KUsEFdY4014mQZMsjzItODWlqkwMtUJdUTaV9d8NGY_J8lkBy7aWhhMq2x8v_fpzls3I4NmNwfL6XTwO3SxPJxIxDw2zmAFO-OY1nd2_1-aB3XNPXBygLO7Kh6_ghv8KtNvbpGAb4tPr5dZZXfN-HYX2_Goi0uXb2C_AZRk6L_5LezoeQ9e-BaTmx68vGouz3twcuNpqjen5LaruqpOyQm56QisrUzvD-bIuEJd0oq_g_GQ-GNBLM61jyvvNkmB_T1mCFnJwpCpqzepN6RekHPk9cQqlYws9ape2-NX2enru79kOpuhj9XVexhffr-9GAVNU4agYHFYB8YiBNxWkcXGgstCIGDUIU2yONGRxeo6ygUXupSxCHkq85LRQrKCGhpnYajpAezOF3P9AUgUl9yIyCD_DkvsapyWUhiBFPsm56IPrFWFKhrGcmycMVNdaprVoEINKpkqp0HF-3D2ILb0lB1PCaStntUj21M2rDwlevTILroX8igNuezD59ZOlD23eBmTzfViXalIRO7XxPYZwsHziPbhwBvYw-JSIKVO9PH5330Ir1xxpcvL-QS79Wqtjyy6qvNjd3yOYW_449fo-h_pBBxx |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED66lG2FMbZspdnWVQ-jbFA3tmVL1mNWVtK1CYUlI2_CP6QtEJIQOw_576eT7Jo-hMLejNDJRne6-7DuvgP4UuSIK4zxxqxIvEhEmZcqzowtU65FomJqibRHYzacRj9n8ewArppaGEyrrH2_8-nWW9cj_Xo3--v5vP_Lt7HcnwnEPCbOPIPDKDY-uQOHg5vb4bjN9KC2vwfO91CgLeRxi9jBryL5Ztfx2L4Q9WqdlmbjtOt4sR-S2tB0_QZe15iSDNxnv4UDtezCc9dlcteFF6P6_rwL5_eOqXp3QSZt4VV5Qc7JfcthbWS6vzFNxtbqkkb8HUwHxJ0MYqCuedw4z0lybPGxQNRKVprMbclJtSPVinxHak8sVEnJWm2qrTmBpZm-_fOXzBcLdLOqfA_T6x-Tq6FX92Xw8ij0K08bkIDbytNQG3yZc8SMyqdxGsYqMHBdBRlnXBUi5D5LRFZENBdRTjUNU99X9Bg6y9VSnQAJwoJpHmik4IlisxqjheCaI8u-zhjvQdSoQuY1aTn2zljINjvNaFCiBqVIpNWgZD24fBBbO9aOpwSSRs_ykflJE1meEj19ZBftC1mQ-Ez04KyxE2mOLt7HpEu12pYy4IH9O7F_BrcIPaA9OHYG9rC44MiqE3z4_-8-g5fDyehO3t2Mbz_Cka21tGk6n6BTbbbq1ICtKvtcH6Z_kS0fHA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+search+for+serologic+correlates+of+immunity+to+Bordetella+pertussis+cough+illnesses&rft.jtitle=Vaccine&rft.au=Cherry%2C+J+D&rft.au=Gornbein%2C+J&rft.au=Heininger%2C+U&rft.au=Stehr%2C+K&rft.date=1998-12-01&rft.issn=0264-410X&rft.volume=16&rft.issue=20&rft.spage=1901&rft.epage=1906&rft_id=info:doi/10.1016%2FS0264-410X%2898%2900226-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |